Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer - Wikidata - wikimedia - TriplyDB

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer

http://www.wikidata.org/entity/Q33388412

about

Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Developments in metastatic pancreatic cancer: is gemcitabine still the standard?First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

P2860

Q28082919-F6DF2A23-41A8-4F56-9C07-690A933B3C2F Q35776091-14A34A44-1BAB-4997-A5A0-6CD04C354D1D Q37050472-B963E0FF-C225-4DAA-900D-FF3F1D154FE0

P2860

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer

http://www.wikidata.org/entity/Q33388412

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Fixed-dose-rate gemcitabine: a ...... eatic and biliary tract cancer

@ast

Fixed-dose-rate gemcitabine: a ...... eatic and biliary tract cancer

@en

type

label

Fixed-dose-rate gemcitabine: a ...... eatic and biliary tract cancer

@ast

Fixed-dose-rate gemcitabine: a ...... eatic and biliary tract cancer

@en

prefLabel

Fixed-dose-rate gemcitabine: a ...... eatic and biliary tract cancer

@ast

Fixed-dose-rate gemcitabine: a ...... eatic and biliary tract cancer

@en

P1433

Q33388412-A24238D7-C207-4DC4-B947-85BA2F26D059

P1476

Q33388412-DB31D3C9-9EA9-405B-9429-5E25497F0A2F

P2093

Q33388412-50276510-9860-4CD7-B87E-EA676EFE0A49

Q33388412-5316BF2A-4E6B-4799-84FF-5E2536B163F1

Q33388412-6666477A-CE1D-46BA-A331-F99D2E5DDAB0

Q33388412-67C3AFDB-3954-49B1-8495-56D71B01F5BD

Q33388412-928D45A8-4A50-4821-8A84-75DDDB29E623

Q33388412-9A95A644-B345-4BD8-98FC-1E89FEA34C71

P2860

Q33388412-2E37D587-4713-457D-A97F-FD96568E3CB1

Q33388412-CF3F4233-E394-4E64-9888-F4FE696795FB

Q33388412-D9076B70-BCA6-4F7F-B553-2078F1FFEFF2

Q33388412-E02719E9-03F4-4402-B8F2-53D587436C97

Q33388412-E61164D2-AFB9-41FC-B5A8-3DF87305B402

Q33388412-EFF3B554-FB23-4F28-B97D-38DFF0ADB8D6

Q33388412-F719F64A-A0B1-447A-B7B1-D697ED83C8D5

P304

Q33388412-168365D8-571B-404C-A72A-F783E29C05DE

P31

Q33388412-9E0EFB60-39D4-49A7-9C6A-4FC2258F6B8E

P356

Q33388412-73CEC4F1-3E83-48A9-917E-422B39A7DD4F

P433

Q33388412-C79CA217-C6CA-49BE-9F99-FA7701400E76

P478

Q33388412-5B6A0ABB-8B65-45F3-A36E-37BE1E911140

P50

Q33388412-D06645E8-210D-482A-B723-49DD70BDD4E1

P577

Q33388412-B2D2932F-6F55-49E3-BACD-127935AD7240

P5875

Q33388412-BE8C0E0C-AAEE-4639-B371-3A0E5B26D6BF

P698

Q33388412-F5D5D15F-76FA-4752-AA08-110CB503CFD4

P932

Q33388412-4160454B-3DBA-488A-8A51-51C604FE54C3

P356

THEONCOLOGIST.2008-0135

P1433

P1476

Fixed-dose-rate gemcitabine: a ...... eatic and biliary tract cancer

@en

P2093

Alain J Gelibter

http://www.w3.org/2001/XMLSchema#string

Francesco Cognetti

http://www.w3.org/2001/XMLSchema#string

Giandominik Bossone

http://www.w3.org/2001/XMLSchema#string

Maria Simona Pino

http://www.w3.org/2001/XMLSchema#string

Michele Milella

http://www.w3.org/2001/XMLSchema#string

Paolo Marolla

http://www.w3.org/2001/XMLSchema#string

P2860

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.

Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature.

Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.

New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

P304

e1-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2008-0135

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Isabella Sperduti

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41622561

http://www.w3.org/2001/XMLSchema#string

P698

20189980

http://www.w3.org/2001/XMLSchema#string

P932

3227937

http://www.w3.org/2001/XMLSchema#string